Study design
DISEASE
The site operates a pregnancy surveillance system through which women were identified for enrolment in the mCARE‐II trial, which evaluated the effect of a mHealth intervention in antenatal and postnatal care coverage (clinical registration No. NCT02909179). Data on the characteristics of women enroled in the mCARE‐II trial were collected through an interview scheduled at the time of pregnancy identification and included women's age and education, husbands' occupation, and household size and asset ownership.Infants born to women enroled in the mCARE‐II trial who reached 3 months of age during a 1‐year enrolment period (September 2018–September 2019) were considered eligible for a trial evaluating the independent and combined effects of a protein intervention and enteric pathogen control intervention on linear growth. For this trial, clusters were randomised to presumptive treatment with azithromycin or a placebo at 6 and 9 months of age and to one of three nutrition interventions (provision of a daily egg, a protein‐rich blended food or a control blended food) or the control. Nutrition education was provided to all arms and consisted of age‐specific messages on infant and young child feeding, which included feeding animal products (e.g., fish, egg, liver) daily with Protocols were approved by the Institutional Review Board of the Johns Hopkins Bloomberg School of Public Health (Baltimore, MD) and the Research and Ethics Review Committee of the International Center for Diarrhoeal Disease Research, Bangladesh (Dhaka, Bangladesh).